

[005a] In an aspect, the present disclosure refers to the use of a composition in the manufacture of a medicament for treating or suppressing an Adenoid Cystic Carcinoma (ACC) tumor in a subject, wherein the composition comprises:



(1).

[005b] In another aspect, the present disclosure refers to the use of a composition in the manufacture of a medicament for inhibiting tumor growth in a subject with an Adenoid Cystic Carcinoma (ACC) tumor, wherein the composition comprises:




(1).

CLAIMS


What is claimed is:

1. Use of a composition in the manufacture of a medicament for treating or suppressing an Adenoid Cystic Carcinoma (ACC) tumor in a subject, wherein the composition comprises:



(1).

2. Use of a composition in the manufacture of a medicament for inhibiting tumor growth in a subject with an Adenoid Cystic Carcinoma (ACC) tumor, wherein the composition comprises:



(1).

3. The use of any one of claims 1-2, wherein said composition is formulated for administration at a dose of 4 mg.
4. The use of any one of claims 1-2, wherein said composition is formulated for administration at a dose of 6 mg.
5. The use of any one of claims 1-2, wherein said composition is formulated for administration at a dose of 0.3, 0.6, 1.2, 2.4, or 8.4 mg.
6. The use of any one of claims 1-5, wherein said composition is formulated for administration once per week.
7. The use of any one of claims 1-5, wherein said composition is formulated for administration once every two weeks.
8. The use of any one of claims 1-7, wherein said ACC tumor comprises tubular ACC, cribriform ACC, or solid ACC.
9. The use of any one of claims 1-8, wherein said ACC tumor comprises a Notch mutation.

10. The use of claim 9, wherein said Notch mutation comprises a Notch-activating mutation.
11. The use of claim 10, wherein said Notch-activating mutation comprises a Notch1 mutation, a Notch2 mutation, a Notch3 mutation, a Notch4 mutation, or a combination thereof.
12. The use of any one of claims 10-11, wherein said Notch-activating mutation perturbs the structure of the negative regulatory region (NRR) of the Notch gene, functionally inactivates the PEST domain of the Notch gene, or a combination thereof.
13. The use of any one of claims 10-12, wherein said Notch-activating mutation comprises a sequence variant in the NRR domain, PEST domain, or combination thereof of a Notch gene.
14. The use of any one of claims 10-13, wherein said Notch-activating mutation comprises a gene rearrangement in the ectodomain of a Notch gene.
15. The use of claim 14, wherein said gene rearrangement removes most of the NRR.